Back to Search
Start Over
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma:EORTC 1205
- Source :
- Raskin , J , Surmont , V , Maat , A P W M , Yahia , M , Burgers , S A , Pretzenbacher , Y , De Ryck , F , Cornelissen , R , Klomp , H M , Oliveira , A , Aerts , J , Baas , P , Marreaud , S , Van Meerbeeck , J P & Van Schil , P E Y 2024 , ' A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma : EORTC 1205 ' , The European respiratory journal , vol. 63 , no. 6 .
- Publication Year :
- 2024
-
Abstract
- BACKGROUND: The role of surgery in pleural mesothelioma remains controversial. It may be appropriate in highly selected patients as part of a multimodality treatment including chemotherapy. Recent years have seen a shift from extrapleural pleuropneumonectomy toward extended pleurectomy/decortication. The most optimal sequence of surgery and chemotherapy remains unknown. METHODS: EORTC-1205-LCG was a multicentric, noncomparative phase 2 trial, 1:1 randomising between immediate (arm A) and deferred surgery (arm B), followed or preceded by chemotherapy. Eligible patients (Eastern Cooperative Oncology Group 0-1) had treatment-naìˆve, borderline resectable T1-3 N0-1 M0 mesothelioma of any histology. Primary outcome was rate of success at 20 weeks, a composite end-point including 1) successfully completing both treatments within 20 weeks; 2) being alive with no signs of progressive disease; and 3) no residual grade 3-4 toxicity. Secondary end-points were toxicity, overall survival, progression-free survival and process indicators of surgical quality. FINDINGS: 69 patients were included in this trial. 56 (81%) patients completed three cycles of chemotherapy and 58 (84%) patients underwent surgery. Of the 64 patients in the primary analysis, 21 out of 30 patients in arm A (70.0%; 80% CI 56.8-81.0%) and 17 out of 34 patients (50.0%; 80% CI 37.8-62.2%) in arm B reached the statistical end-point for rate of success. Median progression-free survival and overall survival were 10.8 (95% CI 8.5-17.2) months and 27.1 (95% CI 22.6-64.3) months in arm A, and 8.0 (95% CI 7.2-21.9) months and 33.8 (95% CI 23.8-44.6) months in arm B. Macroscopic complete resection was obtained in 82.8% of patients. 30- and 90-day mortality were both 1.7%. No new safety signals were found, but treatment-related morbidity was high. INTERPRETATION: EORTC 1205 did not succeed in selecting a preferred sequence of pre- or post-oper
Details
- Database :
- OAIster
- Journal :
- Raskin , J , Surmont , V , Maat , A P W M , Yahia , M , Burgers , S A , Pretzenbacher , Y , De Ryck , F , Cornelissen , R , Klomp , H M , Oliveira , A , Aerts , J , Baas , P , Marreaud , S , Van Meerbeeck , J P & Van Schil , P E Y 2024 , ' A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma : EORTC 1205 ' , The European respiratory journal , vol. 63 , no. 6 .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1452811607
- Document Type :
- Electronic Resource